Manufactured Red Blood Cells (mRBCs)

About Safi Biotherapeutics

Safi Biotherapeutics is a private, pre-clinical stage biotech founded in 2020 to address global blood shortages by manufacturing red blood cells at scale. Leveraging over $20M in non-dilutive government funding and strategic partnerships, the company has developed a proprietary biomanufacturing process for high-density mRBC production and is exploring advanced cryopreservation. With key regulatory designations for sickle cell disease and a clear path toward clinical trials, Safi is positioning itself as a leader in the field of cellular therapeutics for transfusion medicine.

About Safi Biotherapeutics

Safi Biotherapeutics is a private, pre-clinical stage biotech founded in 2020 to address global blood shortages by manufacturing red blood cells at scale. Leveraging over $20M in non-dilutive government funding and strategic partnerships, the company has developed a proprietary biomanufacturing process for high-density mRBC production and is exploring advanced cryopreservation. With key regulatory designations for sickle cell disease and a clear path toward clinical trials, Safi is positioning itself as a leader in the field of cellular therapeutics for transfusion medicine.

Therapeutic Areas